Brokerages Set AngioDynamics, Inc. (ANGO) Target Price at $18.00

AngioDynamics, Inc. (NASDAQ:ANGO) has been given an average recommendation of “Hold” by the eight brokerages that are covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $18.00.

Several research firms have recently issued reports on ANGO. BidaskClub raised AngioDynamics from a “hold” rating to a “buy” rating in a report on Friday. Zacks Investment Research cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Friday, January 26th. Craig Hallum cut shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Finally, TheStreet cut shares of AngioDynamics from a “b-” rating to a “c” rating in a report on Tuesday, January 2nd.

How to Become a New Pot Stock Millionaire

Institutional investors have recently modified their holdings of the company. Fenimore Asset Management Inc. raised its stake in AngioDynamics by 0.6% during the 4th quarter. Fenimore Asset Management Inc. now owns 594,490 shares of the medical instruments supplier’s stock worth $9,886,000 after buying an additional 3,715 shares during the period. First Trust Advisors LP raised its stake in AngioDynamics by 13.7% during the fourth quarter. First Trust Advisors LP now owns 32,866 shares of the medical instruments supplier’s stock worth $547,000 after purchasing an additional 3,968 shares during the period. Legal & General Group Plc raised its stake in AngioDynamics by 7.0% during the third quarter. Legal & General Group Plc now owns 65,557 shares of the medical instruments supplier’s stock worth $1,119,000 after purchasing an additional 4,296 shares during the period. Highbridge Capital Management LLC raised its stake in AngioDynamics by 21.4% during the third quarter. Highbridge Capital Management LLC now owns 25,304 shares of the medical instruments supplier’s stock worth $432,000 after purchasing an additional 4,461 shares during the period. Finally, Nordea Investment Management AB raised its stake in AngioDynamics by 5.8% during the third quarter. Nordea Investment Management AB now owns 126,040 shares of the medical instruments supplier’s stock worth $2,154,000 after purchasing an additional 6,948 shares during the period. Institutional investors and hedge funds own 97.09% of the company’s stock.

NASDAQ:ANGO traded up $0.37 during trading hours on Friday, reaching $17.25. The company had a trading volume of 943,775 shares, compared to its average volume of 204,400. AngioDynamics has a one year low of $14.80 and a one year high of $18.85. The stock has a market capitalization of $633.85, a price-to-earnings ratio of 23.96, a price-to-earnings-growth ratio of 1.60 and a beta of 1.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.56 and a quick ratio of 1.65.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Thursday, March 29th. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.05. The firm had revenue of $83.85 million for the quarter, compared to analysts’ expectations of $86.13 million. AngioDynamics had a positive return on equity of 4.63% and a negative net margin of 2.27%. research analysts expect that AngioDynamics will post 0.72 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by WKRB News and is the sole property of of WKRB News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.wkrb13.com/2018/04/01/brokerages-set-angiodynamics-inc-ango-target-price-at-18-00.html.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.

Analyst Recommendations for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply